Cargando…
FIST, a sword and shield fusokine for cancer immunotherapy
To antagonize tumor-derived TGFβ contemporaneously to anticancer immunotherapy, we genetically engineered a fusion protein coupling IL-2 and the ectodomain of TGFβ receptor II (Fusion of Interleukin-2 and Soluble TGFβ receptor – a.k.a. FIST). FIST possesses intriguing gain-of-function properties and...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Landes Bioscience
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3376982/ https://www.ncbi.nlm.nih.gov/pubmed/22720250 http://dx.doi.org/10.4161/onci.1.2.18458 |